CD274 and cancer: A possibility to overcome this current lack of clinical translationcould be the combination of cancer-specific antibodies (Abs), especiallythose already established in clinics, such as anti-human epidermalgrowth factor receptor 2 or anti-programmed death ligand 1 (anti-PD-L1)Abs, with NP-based drug-delivering vectors.